ImprimisRX
challenging their people, demonstrating a “can-do” attitude, and fostering a collaborative and mutually supportive environment. For more information, please visit www.ImprimisRx.com.
Compounded Combination Ophthalmic Drops – Benefits for Patients and Surgeons Alike. While cataract and refractive procedures are among the most frequently performed surgeries, the outcomes are somewhat dependent on an often complex post-op medication regimen that must be carried out by the patient.
Undergoing surgery can be daunting to individuals and going home afterward with a complicated list of when and how to take your medications can be overwhelming. Traditionally, patients have been prescribed three different eye drops to counteract the risk of infection, pain, and inflammation after cataract surgery. Depending on the specific procedure employed by the surgeon, patients may need to apply one eye drop up to 4 times per day for as many as 30 days, another eyedrop up to 4 times per day for as many as 7 days, and a third eyedrop once daily for 30 days. Easy Does It Forward thinking eye surgeons are moving past this complex and counter-intuitive post-op regimen.
What Are Compounded Medications? ImprimisRx® Breaks Down the Function and Importance of These Unique Pharmaceuticals – The Official Health blog. Compounded medications deliver active ingredients in a form that best meets the needs of the patient.
ImprimisRx takes the benefits of traditional compounding for ophthalmic patients two steps further and eliminates pickup hassles and lowers costs. Why would patients with the most common eye diseases of aging prefer compounded drugs from ImprimisRx? Why would physicians prefer to deal with ImprimisRx? ImprimisRX Wants to Help You Deliver Top-Notch Customer Service to Your Pharmaceutical Clients - EIN Presswire. ImprimisRX Advises on How to Deliver a Consistently Exceptional Customer Service Experience SAN DIEGO, CA, UNITED STATES, August 12, 2021 /EINPresswire.com/ -- When it comes to providing an essential service that many people rely on, impeccable customer service must be prioritized.
ImprimisRX understands that its customers must receive top-notch service to remain competitive. They value the needs of their pharmaceutical clients and ensure that they always keep their clients satisfied. They want to encourage this culture of attention to our clients to develop and further grow their business, while also retaining that business at the same time. Compounded cyclosporine may be option for dry eye treatment. Source/Disclosures Published by: Disclosures: Matossian reports she is a consultant for Allergan, ImprimisRx, Novartis and Sun Ophthalmics.
Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery. SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion.
The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. Imprimis CEO, Mark L. EyePoint, ImprimisRx enter Dexycu commercial alliance. August 04, 2020 1 min read Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on .
ImprimisRx’s Patented Klarity-C® 0.1% Cyclosporine Preservative-Free Formulation May Now Be Prescribed By Florida’s 2,000 Optometrists. Press release content from Globe Newswire.
The AP news staff was not involved in its creation. SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Klarity-C preservative-free formulation (0.1% cyclosporine emulsion) may now be prescribed by Florida’s nearly 2,000 optometrists¹ as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents. Klarity-C, which has been prescribed for thousands of Americans in all 50 states, was recently recognized at a Best of Saturday Sessions presentation at the 2020 ASCRS Annual Meeting in a presentation entitled “Efficacy of Topical 0.1% Cyclosporine in Chondroitin Sulfate Ophthalmic Emulsion in Patients with Dry Eye” ( click here to view the abstract).
About ImprimisRx. ImprimisRx® Announces Supply Agreement with Vision Center Network of America (VCNA) SAN DIEGO, March 03, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, and a wholly-owned subsidiary of Harrow Health, Inc.
(NASDAQ: HROW), announced that it has agreed to a product supply agreement with Vision Center Network of America, LLC (VCNA). The agreement will make ImprimisRx a VCNA preferred provider for a variety of surgical formulations, including a portfolio of topical and injectable products. VCNA is a clinically integrated network (CIN) of ophthalmic ambulatory surgery centers (ASCs) currently serving patients primarily in the New York and New Jersey area. ImprimisRx to Focus on Investments in Quality at the 2019 American Academy of Ophthalmology Meeting. ImprimisRx’s FDA-Registered Outsourcing Facility Issued. SAN DIEGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc.
(NASDAQ: HROW), announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California. This license allows California-based ophthalmologists, optometrists, surgery centers and hospitals to efficiently order and stock ImprimisRx’s more than 40 ophthalmic products for on-demand administration to their patients. John Saharek, President of ImprimisRx, commented, “Our team is excited to begin serving our home state of California, and its nearly 40 million residents, with high-quality ophthalmic formulations from our FDA-registered 503B outsourcing facility.
EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx. WATERTOWN, Mass. and NASHVILLE, Tenn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.
(NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly-owned subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced the signing of a commercial alliance for the joint promotion of DEXYCU® (dexamethasone intraocular suspension) 9% for the treatment of post-operative inflammation following ocular surgery in the U.S.
“EyePoint is excited to collaborate with the ImprimisRx team to expand the commercial reach of DEXYCU to cataract surgeons and patients in need of more effective treatments to manage ocular inflammation following surgery,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. About EyePoint PharmaceuticalsEyePoint Pharmaceuticals, Inc. Yahoo fait désormais partie de Verizon Media. Leading Peer-Reviewed Ophthalmic Journal Publishes Study on. NASHVILLE, Tenn., May 17, 2021 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business and a wholly owned subsidiary of Harrow Health, Inc.
(NASDAQ: HROW), today announced that a study of its Klarity-C Drops® (cyclosporine 0.1% ophthalmic emulsion PF) has been published in the peer-reviewed journal, Clinical Ophthalmology.1 Klarity-C is a compounded cyclosporine eye drop currently prescribed by thousands of doctors across the United States. The preservative-free drop contains an emulsion with chondroitin sulfate and the active ingredient cyclosporine 0.1%, which has long been used to improve tear quality.2-4.